Sign In
Buy AVRO
$1.40
+0 (+0%)
At Close: Sep 19, 2024
AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials
11:00am, Monday, 06'th Jul 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the first patient has been dosed in t
Squarepoint Ops LLC Sells 25,590 Shares of Avrobio Inc (NASDAQ:AVRO)
06:22am, Saturday, 04'th Jul 2020
Squarepoint Ops LLC reduced its position in shares of Avrobio Inc (NASDAQ:AVRO) by 51.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund o
Analyzing Avrobio (NASDAQ:AVRO) & Editas Medicine (NASDAQ:EDIT)
02:54am, Tuesday, 30'th Jun 2020
Avrobio (NASDAQ:AVRO) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their ins
AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer
11:00am, Monday, 29'th Jun 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Kim Raineri, as chief m
Here is What Hedge Funds Think About AVROBIO, Inc. (AVRO)
08:16pm, Wednesday, 24'th Jun 2020
In this article you are going to find out whether hedge funds think AVROBIO, Inc. (NASDAQ:AVRO) is a good investment right now. We like to check what the smart money thinks first before doing extensiv
Cowen & Co. Maintains a Buy Rating on IVERIC bio (ISEE) - Markets
12:47pm, Wednesday, 17'th Jun 2020
Cowen & Co. analyst Ken Cacciatore maintained a Buy rating on IVERIC bio (ISEE – Research Report) on June 15
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to...
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential
Global Leukemia Therapeutics Market Forecast and Opportunities to 2025 - ResearchAndMarkets.com
12:00am, Thursday, 11'th Jun 2020
The
Repligen: Management Gambled With 2020 Guidance But Long-Term Growth Story Looks Compelling (NASDAQ:RGEN)
05:04pm, Wednesday, 10'th Jun 2020
Repligen develops and sells bioprocessing technologies and systems involved in the manufacturing of biological drugs. The company operates within a high growth,
Somebody tell Mesoblast we get the message
01:31pm, Wednesday, 03'rd Jun 2020
Mesoblast has now put out at least nine announcements since April 9 covering the same potential treatment for COVID-19.
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
12:00am, Sunday, 24'th May 2020
Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Surface Oncology Inc (...
City of Hope Physicians/Scientists Lead Multiple, Innovative COVID-19 Research Projects
12:00am, Thursday, 21'st May 2020
City of Hope’s physician-scientists and basic scientists are using their expertise to attack the deadly coronavirus on multiple research fronts.
AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020
11:00am, Thursday, 14'th May 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new preclinical data for AVR-RD-03 for Pom
